日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Combining genetic proxies of drug targets and time-to-event analyses from longitudinal observational data to identify target patient populations

结合药物靶点的遗传代理指标和来自纵向观察数据的生存时间分析，以确定目标患者群体

期刊:BMC Cardiovascular Disorders
影响因子:2.3
doi:10.1186/s12872-025-04753-1
Zhang, Luke; Kulkarni, Prachi; Farshidfar, Farshad; Tingley, Whit; Hoey, Tim; Wang, Whedy; Priest, James R; Figarska, Sylwia M
发表日期：2025
文献求助 收藏

Statistical considerations when estimating time-saving treatment effects in Alzheimer's disease clinical trials

在阿尔茨海默病临床试验中评估节省时间治疗效果时的统计学考虑因素

期刊:Alzheimers & Dementia
影响因子:11.1
doi:10.1002/alz.14035
Wang, Guoqiao; Cutter, Gary; Oxtoby, Neil P; Shan, Guogen; Wang, Whedy; Mangal, Brian; Liao, Yijie; Llibre-Guerra, Jorge J; Li, Yan; Xiong, Chengjie; McDade, Eric; Delmar, Paul; Bateman, Randall J; Schneider, Lon
阿尔茨海默症
发表日期：2024
文献求助 收藏

Novel non-linear models for clinical trial analysis with longitudinal data: A tutorial using SAS for both frequentist and Bayesian methods

用于纵向数据临床试验分析的新型非线性模型：使用 SAS 进行频率学派和贝叶斯方法的教程

期刊:Statistics in Medicine
影响因子:1.8
doi:10.1002/sim.10089
Wang, Guoqiao; Wang, Whedy; Mangal, Brian; Liao, Yijie; Schneider, Lon; Li, Yan; Xiong, Chengjie; McDade, Eric; Kennedy, Richard; Bateman, Randall; Cutter, Gary
发表日期：2024
文献求助 收藏

Safety and efficacy of ampreloxetine in symptomatic neurogenic orthostatic hypotension: a phase 2 trial

安普洛西汀治疗症状性神经源性体位性低血压的安全性和有效性：一项 II 期试验

期刊:Clinical Autonomic Research
影响因子:3.4
doi:10.1007/s10286-021-00827-0
Kaufmann, Horacio; Vickery, Ross; Wang, Whedy; Kanodia, Jitendra; Shibao, Cyndya A; Norcliffe-Kaufmann, Lucy; Haumann, Brett; Biaggioni, Italo
发表日期：2021
文献求助 收藏

Telavancin in the Treatment of Concurrent Staphylococcus aureus Bacteremia: A Retrospective Analysis of ATLAS and ATTAIN Studies

特拉万星治疗并发金黄色葡萄球菌菌血症：ATLAS 和 ATTAIN 研究的回顾性分析

期刊:Infectious Diseases and Therapy
影响因子:4.7
doi:10.1007/s40121-017-0162-1
Samuel E Wilson, Donald R Graham, Whedy Wang, Jon B Bruss, Bibiana Castaneda-Ruiz
发表日期：2017
文献求助 收藏

Assessment of Minimum Inhibitory Concentrations of Telavancin by Revised Broth Microdilution Method in Phase 3 Hospital-Acquired Pneumonia/Ventilator-Associated Pneumonia Clinical Isolates

用修订的肉汤微量稀释法评估 3 期医院获得性肺炎/呼吸机相关性肺炎临床分离株中特拉万星的最低抑菌浓度

期刊:Infectious Diseases and Therapy
影响因子:4.7
doi:10.1007/s40121-016-0133-y
Jennifer I Smart, Gordon Ralph Corey, Martin E Stryjewski, Whedy Wang, Steven L Barriere
免疫
肺炎
发表日期：2016
文献求助 收藏

Telavancin for Acute Bacterial Skin and Skin Structure Infections, a Post Hoc Analysis of the Phase 3 ATLAS Trials in Light of the 2013 FDA Guidance

特拉万星治疗急性细菌性皮肤及皮肤结构感染：基于2013年FDA指南的3期ATLAS试验事后分析

期刊:Antimicrobial Agents and Chemotherapy
影响因子:4.5
doi:10.1128/AAC.00471-15
Pushkin, Richard; Barriere, Steven L; Wang, Whedy; Corey, G Ralph; Stryjewski, Martin E
炎症/感染
微生物学
发表日期：2015
文献求助 收藏